Merck & Co., Inc. (MRK), Bristol Myers Squibb Co. (BMY): Breakthrough Melanoma Data Drives Pharmas Higher

Yesterday’s exciting results have already revived investor enthusiasm in both companies, with Merck up more than 4.5% and Bristol Myers Squibb Co. (NYSE:BMY) up more than 5.5% in intraday trading. With lambrolizumab given breakthrough therapy designation in April and nivolumab granted fast-track status by the FDA for three cancer indications, both drugs have the potential to rapidly progress through late-stage clinical trials and hit the market earlier than expected.

The article Breakthrough Melanoma Data Drives Pharmas Higher originally appeared on Fool.com.

Max Macaluso, Ph.D., has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.